Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
Giacomo Bregni(Institut Jules Bordet), Francesco Sclafani(Royal Marsden NHS Foundation Trust), Elena Trevisi(Université Libre de Bruxelles), Andrea Pretta(University of Cagliari), Karen Geboes(Universitair Ziekenhuis Leuven), Luigi Moretti(Université Libre de Bruxelles), Jean‐Luc Van Laethem(Deventer Ziekenhuis), Marc Peeters(University of Antwerp), Chiara Senti(Istituti Ospitalieri di Cremona), Camille Anastasia Chapot(Université Libre de Bruxelles), Caroline Vandeputte(KU Leuven), Javier Carrasco(Grand Charleroi Hospital), Philippe Vergauwe, Alain Hendlisz(London Cancer), Amélie Deleporte(Université Libre de Bruxelles), Pashalina Kehagias(Université Libre de Bruxelles), Lionel D’Hondt(CHU Dinant Godinne UCL Namur), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Yeter Gökburun(Centre Hospitalier Régional de Namur), Patrick Flamen(Université Libre de Bruxelles), Pieter Demetter(Université Libre de Bruxelles), Marc Buyse(Institut des Arts de Diffusion), Elena Acedo Reina(Université Libre de Bruxelles), Marc Van den Eynde(Cliniques Universitaires Saint-Luc), Gabriel Liberale(Institut Jules Bordet)
Cited by 11
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
|JNCI Journal of the National Cancer Institute|2006|1.2k